IgM-phosphorylcholine autoantibodies and outcome in acute coronary syndromes

International Journal of Cardiology

Volumn 167, Issue 2, 2013, Pages 464-469

  Caidahl, Kenneth ^a,b,d   Hartford, Marianne ^d   Karlsson, Thomas ^d   Herlitz, Johan ^e   Pettersson, Knut ^c   De Faire, Ulf ^a,b   Frostegård, Johan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Athera Biotechnologies   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF BORÅS   (Sweden)

Author keywords

Angina; Antibodies; Immune system; Myocardial infarction; Prognosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; IMMUNOGLOBULIN M; PHOSPHORYLCHOLINE; TROPONIN I;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ACUTE CORONARY SYNDROME; AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PHOSPHORYLCHOLINE; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84879105292     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.01.018     Document Type: Article

References (39)

1. C.J. Binder, K. Hartvigsen, and M.K. Chang IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis J Clin Invest 114 2004 427 437
2. M.Y. Chou, L. Fogelstrand, and K. Hartvigsen Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans J Clin Invest 119 2009 1335 1349
3. Y.I. Miller, S.H. Choi, and P. Wiesner Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity Circ Res 108 2011 235 248
4. P. Libby, P.M. Ridker, and G.K. Hansson Inflammation in atherosclerosis: from pathophysiology to practice J Am Coll Cardiol 54 2009 2129 2138
5. M.L. O'Donoghue, Z. Mallat, and D.A. Morrow Prognostic utility of secretory phospholipase A2 in patients with stable coronary artery disease Clin Chem 57 2011 1311 1317
6. M.B. Pepys, G.M. Hirschfield, and G.A. Tennent Targeting C-reactive protein for the treatment of cardiovascular disease Nature 440 2006 1217 1221
7. R.L. Wilensky, Y. Shi, and E.R. Mohler III Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development Nat Med 14 2008 1059 1066
8. D.A. Morrow, and J.A. de Lemos Benchmarks for the assessment of novel cardiovascular biomarkers Circulation 115 2007 949 952
9. R.R. Packard, and P. Libby Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction Clin Chem 54 2008 24 38
10. U. de Faire, J. Su, and X. Hua Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism J Autoimmun 34 2010 73 79
11. J. Frostegard, Y.H. Huang, J. Ronnelid, and L. Schafer-Elinder Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism Arterioscler Thromb Vasc Biol 17 1997 963 968
12. C.J. Binder, M.K. Chang, and P.X. Shaw Innate and acquired immunity in atherogenesis Nat Med 8 2002 1218 1226
13. R. Fiskesund, B. Stegmayr, and G. Hallmans Low levels of antibodies against phosphorylcholine predict development of stroke in a population-based study from Northern Sweden Stroke 41 2010 00
14. J. Su, A. Georgiades, R. Wu, T. Thulin, U. de Faire, and J. Frostegard Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension Atherosclerosis 188 2006 160 166
15. J. Su, X. Hua, H. Concha, E. Svenungsson, A. Cederholm, and J. Frostegard Natural antibodies against phosphorylcholine as potential protective factors in SLE Rheumatology 47 2008 1144 1150 (Oxford).
16. M. Hartford, O. Wiklund, and L. Mattsson Hulten C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes J Intern Med 262 2007 526 536
17. T. Omland, T. Ueland, and A.M. Jansson Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes J Am Coll Cardiol 51 2008 627 633
18. B.G. Sjoberg, J. Su, and I. Dahlbom Low levels of IgM antibodies against phosphorylcholine - a potential risk marker for ischemic stroke in men Atherosclerosis 203 2009 528 532
19. C.S. Lam, J.C. Burnett Jr., L. Costello-Boerrigter, R.J. Rodeheffer, and M.M. Redfield Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population J Am Coll Cardiol 49 2007 1193 1202
20. W. Harnett, and M.M. Harnett Phosphorylcholine: friend or foe of the immune system? Immunol Today 20 1999 125 129
21. D.E. Briles, C. Forman, S. Hudak, and J.L. Claflin Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae J Exp Med 156 1982 1177 1185
22. C.J. Binder, P.X. Shaw, and M.K. Chang The role of natural antibodies in atherogenesis J Lipid Res 46 2005 1353 1363
23. P.X. Shaw, S. Horkko, and M.K. Chang Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity J Clin Invest 105 2000 1731 1740
24. S.A. Karabina, I. Brocheriou, and G. Le Naour Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function FASEB J 20 2006 2547 2549
25. A.D. Watson, N. Leitinger, and M. Navab Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo J Biol Chem 272 1997 13597 13607
26. M.K. Chang, C.J. Binder, and Y.I. Miller Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory J Exp Med 200 2004 1359 1370
27. S. Horkko, D.A. Bird, and E. Miller Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins J Clin Invest 103 1999 117 128
28. C.J. Binder, S. Horkko, and A. Dewan Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL Nat Med 9 2003 736 743
29. G. Caligiuri, J. Khallou-Laschet, and M. Vandaele Phosphorylcholine- targeting immunization reduces atherosclerosis J Am Coll Cardiol 50 2007 540 546
30. J.R. Faria-Neto, K.Y. Chyu, and X. Li Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice Atherosclerosis 189 2006 83 90
31. S. Tsimikas, Z. Mallat, and P.J. Talmud Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events J Am Coll Cardiol 56 2010 946 955
32. L. Genestier, M. Taillardet, P. Mondiere, H. Gheit, C. Bella, and T. Defrance TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses J Immunol 178 2007 7779 7786
33. M. Hartford, O. Wiklund, and L. Mattsson Hulten CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up Int J Cardiol 108 2006 55 62
34. M.K. Chang, C.J. Binder, M. Torzewski, and J.L. Witztum C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids Proc Natl Acad Sci USA 99 2002 13043 13048
35. R.J. Bisoendial, R.S. Birjmohun, and F. Akdim C-reactive protein elicits white blood cell activation in humans Am J Med 122 582 2009 e581 e589
36. Y. Arnson, Y. Shoenfeld, and H. Amital Effects of tobacco smoke on immunity, inflammation and autoimmunity J Autoimmun 34 2010 J258 J265
37. S. Kiechl, P. Werner, and G. Egger Active and passive smoking, chronic infections, and the risk of carotid atherosclerosis: prospective results from the Bruneck Study Stroke 33 2002 2170 2176
38. J. Hulthe, J. Wikstrand, A. Lidell, I. Wendelhag, G.K. Hansson, and O. Wiklund Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia Arterioscler Thromb Vasc Biol 18 1998 1203 1211
39. P.X. Shaw, C.S. Goodyear, M.K. Chang, J.L. Witztum, and G.J. Silverman The autoreactivity of anti-phosphorylcholine antibodies for atherosclerosis- associated neo-antigens and apoptotic cells J Immunol 170 2003 6151 6157 biotechnology for health